In this communication, we examined the role of the MAP kinase pathway in the G2/M phase of the cell cycle. Activation of the Plk1 and MAP kinase pathways was initially evaluated in FT210 cells, which arrest at G2 phase at the restrictive temperature (391C), due to a mutation in the cdc2 gene. Previous studies had shown that these cells enter mitosis at the nonpermissive temperature upon incubation with okadaic acid, a protein phosphatase 1 and 2A inhibitor. We show that treatment of FT210 cells at 391C with okadaic acid activated Plk1, as shown by hyperphosphorylation and elevated protein kinase activity, and also induced activation of the MAP kinase pathway. The specific Mek inhibitor PD98059 antagonized the okadaic acid-induced activation of both Plk1 and MAP kinases. This suggests that activation of the MAP kinase pathway may contribute to the okadaic acid-induced activation of Plk1 in FT210 cells at 391C. We also found that PD98059 strongly attenuated progression of HeLa cells through mitosis, and active Mek colocalizes with Plk1 at mitotic structures. To study the potential function of the MAP kinase pathway during mitosis, RNAi was used to specifically deplete five members of this pathway (Raf1, Mek1/2, Erk1/2). Each of these five protein kinases is required for cell proliferation and survival, and depletion of any of these proteins eventually leads to apoptosis. Treatment with Mek inhibitors also inhibited cell proliferation and caused apoptosis. A dramatic increase of Plk1 activities and a moderate increase of Cdc2 activities in Raf1-depleted cells indicate that Raf1-depleted cells arrest in the late G2 or M phase. Mek1 and Erk1 depletion also caused cell cycle arrest at G2, suggesting that these enzymes are required for the G2/M transition, whereas the loss of Mek2 or Erk2 caused arrest at G1.
Introduction
Maturation-promoting factor (MPF, Cdc2/cyclin B) is a serine/threonine protein kinase that phosphorylates a repertoire of proteins, including chromatin-associated proteins, cytoskeleton proteins, transcription factors, and other protein kinases (Nigg, 1993) . It plays a pivotal role for cells to enter mitosis, and its activity is tightly regulated during cell cycle progression (Nigg, 1993; Lees, 1995) . At the onset of mitosis, Cdc2/cyclin B is activated due to the removal of inhibitory phosphorylations at Thr14 and Tyr15 on Cdc2, the catalytic subunit, by the dual-specificity phosphatase Cdc25C (Kumagai and Dunphy, 1991) . In addition, high MPF activity at the onset of mitosis also corresponds to a high level of cyclin B, the regulatory subunit, which is targeted for degradation by anaphase-promoting complex at the end of mitosis.
In addition to Cdc2/cyclin B, polo-like kinases (Plks) are also important contributors to cell cycle control (Lane and Nigg, 1997) . Genetic and biochemical experiments in yeast and mammalian cells indicate that Plks regulate diverse mitotic processes, such as centrosome maturation (Lane and Nigg, 1996) , bipolar spindle formation (Ohkura et al., 1995) , sister chromatid separation Erikson, 2002, 2003) , actin ring formation, and cytokinesis (Lee and Erikson, 1997; Liu and Erikson, 2002) . Other reported functions of Plks include activation of Cdc25C, resulting in activation of Cdc2 (Kumagai and Dunphy, 1996) , adaptation to DNA damage (Smits et al., 2000) , and regulation of the anaphase-promoting complex (Descombes and Nigg, 1998) . Plk1 activity is cell-cycle dependent, and regulated by reversible phosphorylation (Lane and Nigg, 1997) . Possible activation of Plk1 by Cdc2/cyclin B is controversial. One study reported that although Plk1 can be phosphorylated by Cdc2/cyclin B in vitro, its activity was not significantly affected (Hamanaka et al., 1995) . Another report indicated that Cdc2/cyclin B purified from recombinant baculovirus-infected cells does phosphorylate and activate Plk1 in vitro (Kotani et al., 1998) . More recently, Stk10, a member of the Ste20 serine/threonine kinase family, was shown to phosphorylate Plk1 (Walter et al., 2003) . It is unclear, however, how Stk10 is regulated.
The mitogen-activated protein (MAP) kinase pathway has been deemed essential for re-entry into the cell cycle from G0 in response to mitogen stimulation. In brief, mitogen-activated cell surface signaling complexes transfer the signal to a protein kinase cascade that involves Raf1, an MAP kinase kinase kinase. Raf1 phosphorylates and activates Mek (MAP kinase kinase), which then phosphorylates and activates Erk (MAP kinase) (Kolch, 2000) . Activated Erk, along with its downstream targets of the Rsk protein kinase family, translocates to the nucleus where they phosphorylate a number of transcription factors (Treisman, 1996) . In addition to its clearly defined role during early phases of the cell cycle, the MAP kinase pathway has also been implicated in later phases of the cell cycle in different systems. In Xenopus oocytes, the MAP kinase pathway is required for the onset of meiosis I during meiotic maturation (Haccard et al., 1995) . In Xenopus egg extracts, although the pathway does not seem to be required for mitotic entry (Takenaka et al., 1997) , activation of MAP kinase pathway is essential for normal mitotic progression (Guadagno and Ferrell, 1998) , and Erk activity is also required for the spindle assembly checkpoint (Minshull et al., 1994; Takenaka et al., 1997) . In mammalian cells, use of a specific inhibitor demonstrated that Mek is involved in the G2/ M transition (Wright et al., 1999) . Furthermore, active phosphorylated forms of MAP kinase pathway members localize at mitotic structures, such as spindle poles, during metaphase/anaphase, and at the midbody during telophase/cytokinesis (Shapiro et al., 1998; Zecevic et al., 1998) . Phosphorylated Erk also localizes to kinetochores and interacts with the motor protein CENP-E during mitosis (Zecevic et al., 1998) . Most recently, it was reported that Mek1 activation during mitosis is due to a Cdc2/cyclin B-dependent proteolytic cleavage of the Nterminal Erk-binding domain (Harding et al., 2003) .
In this communication, we first utilized FT210 cells, which encode a temperature-sensitive Cdc2 protein kinase (Th'ng et al., 1990) , to further evaluate the role of Cdc2 activity in the activation of Plk1. The potential functions of the MAP kinase pathway during cell cycle phases other than G1 and S were also investigated using the specific Mek inhibitor PD98059 to block the activation of the MAP kinase cascade. Furthermore, using vector-based RNAi technology, we evaluated the cellular phenotypes after depletion of five members of the MAP kinase pathway, Raf1, Mek1/2, Erk1/2, as well as the effects of depletion on the activation of Cdc2 and Plk1.
Materials and methods

Vector construction
Plasmids pBS/U6-Raf1, pBS/U6-Mek1, pBS/U6-Mek2, pBS/ U6-Erk1, and pBS/U6-Erk2 were constructed as described previously (Sui et al., 2002) . The targeting sequences are as follows: for human Raf1 (Accession No. NM_002880), GGGCATCAGATGATGGCAAAC, corresponding to the coding region 122-142 relative to the first nucleotide of the start codon; for human Mek1 (Accession No. NM_002755), GGGAGAACTGAAGGATGACGA, corresponding to the coding region 180-200 relative to the first nucleotide of the start codon; for human Mek2 (Accession No. NM_030662), GGGTGGTCACCAAAGTCCAGCA, corresponding to the coding region 251-272 relative to the first nucleotide of the start codon; for human Erk1 (Accession No. M84490), GGGCCTCAAGTACATCCACTC, corresponding to the coding region 369-389 relative to the first nucleotide of the start codon; for human Erk2 (Accession No. M84489), GGGTTCCTGACAGAATATGTGG, corresponding to the coding region 544-565 relative to the first nucleotide of the start codon. Plasmid pBS/U6-Raf1-1st half (sense strand) was used as a control vector for pBS/U6-Raf1. This vector produces RNA that cannot form a hairpin structure to generate interfering RNA. Similar control vectors were used for the other constructs.
EE-tagged Mek1 plasmids, either constitutively active form (pCI-neo-Mek1-DD) or kinase dead form (pCI-neo-Mek1-VV), were constructed as described previously (MacDonald et al., 1993; Huang and Erikson, 1994) .
Cell culture and synchronization FT210 cells were maintained in RPMI medium supplemented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin, and 100 U/ml streptomycin at 331C in 8% CO 2 . Incubation at 391C for 18 h arrests these cells at G2. To obtain mitotic cells, FT210 cells were treated with 200 ng/ml nocodazole for 16 h. HeLa cells were maintained in DMEM medium supplemented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin and 100 U/ ml streptomycin at 371C in 8% CO 2 . To obtain the maximum number of cells in mitosis, HeLa cells were first double thymidine blocked (treated with 2.5 mM thymidine for 16 h, released for 8 h, then blocked for another 16 h) at the late G1 phase, then released into normal growth medium supplemented with 24 mM deoxycytidine and 100 mM monastrol for 12 h to arrest the cells at prometaphase. After three washes with PBS, the cells were further incubated in medium for an additional 30-75 min to obtain cells at various phases of mitosis (Kapoor et al., 2000) .
DNA transfections
HeLa cells were cotransfected with pBS/U6-based vectors and pBabe-Puro at a ratio of 9 : 1 using GenePorter transfection reagent (GTS, San Diego, CA, USA). Cells were seeded at 80% confluence in 10-cm dishes on the day before transfection. A measure of 10 mg of plasmid DNA was diluted with 0.5 ml serum-free DMEM, and mixed with 0.5 ml diluted GenePorter reagent (50 ml reagent diluted with 0.5 ml serum-free DMEM). The mixture was incubated at room temperature for 30 min and then resuspended in 4 ml serum-free DMEM. After the cells were incubated in this mixture at 371C for 4 h, 5 ml DMEM containing 20% serum was added. About 24 h posttransfection, the medium was changed and the culture was further incubated for an additional 36 h in the presence of 2 mg/ ml puromycin. The floating cells were removed and the remaining cells were used for phenotype analysis.
Western blotting
Cells were lysed in TBSN buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 1.5 mM EDTA, 5 mM EGTA, 0.5% Nonidet P-40, 0.5 mM Na 3 VO 4 ) supplemented with 20 mM p-nitrophenyl phosphate and proteinase inhibitors (1 mM Pefabloc, 10 mg/ ml pepstatin A, 10 mg/ml leupeptin, 5 mg/ml aprotinin), and the lysates were clarified by centrifugation at 15 000 Â g for 30 min. Cell lysates were directly resolved by SDS-PAGE and transferred to Immobilon-P membranes (Millipore). To detect hyperphosphorylated Plk1, samples were run on a low bis gel (acrylamide : bisacrylamide ¼ 120 : 1) until the 50 kDa marker reached the bottom. Proteins transferred to the membrane were detected by various antibodies, horseradish peroxidaselinked secondary antibody, and visualized by enhanced chemiluminescence reagents.
Immunofluorescence staining
HeLa cells were grown on coverslips and synchronized as described above. Cells were fixed with 4% paraformaldehyde for 10 min, and permeabilized with methanol for 2 min. After washing with 0.1% Triton X-100/PBS three times, coverslips were blocked with 10% goat serum/PBS for 30 min, double stained with 10 mg/ml anti-Plk1 (mouse) and antiphosphoMek1/2 (rabbit) antibodies for 2 h at room temperature, followed by incubation for 45 min with FITC-conjugated antimouse and Cy3-conjugated anti-rabbit Ig secondary antibodies. Finally, DNA was stained with DAPI. Antibodies against Plk1 and phospho-Mek1/2 were obtained from Zymed (South San Francisco, CA, USA) and Cell Signaling Technology (Beverly, MA, USA), respectively.
IP/kinase assay
Equal amounts (B1 mg) of cell lysates were immunoprecipitated with different antibodies (Plk, Cdc2, Erk1/2, EE) and protein A/G-agarose beads. The immunoprecipitates were incubated with various substrates, as indicated, in a kinase reaction buffer (50 mM Tris, pH 7.5, 10 mM MgCl 2 , 5 mM DTT, 2 mM EGTA, 0.5 mM Na 3 VO 4 , 20 mM p-nitrophenyl phosphate) supplemented with 25 mM ATP and 50 mCi of [g-32 P]ATP. GST-tagged translation-controlled tumor protein (TCTP) was used as a substrate for Plk1 (Yarm, 2002) , and histone H1 and MBP were used as substrates for Cdc2 and Erk1/2, respectively. About 2 mg of substrate was used per assay. The reaction mixtures were incubated at 301C for 30 min and resolved on SDS-polyacrylamide gels. The gels were dried and subjected to autoradiography.
Results
Activation of Plk1 in the absence of Cdc2 activity
Plx1 has been reported to be a component of the MPF amplification loop at the G2/M-phase transition of the cell cycle in Xenopus oocytes (Abrieu et al., 1998; Qian et al., 1999) . To investigate whether Plk1 can be activated in the absence of Cdc2 activity in mammalian cells, we utilized mouse mammary gland carcinoma FT210 cells. These cells grow normally at the permissive temperature (331C), but arrest at G2 phase at the restrictive temperature (391C), because of a temperature-sensitive defect in Cdc2 (Th'ng et al., 1990) . These cells can enter mitosis in the absence of Cdc2 activity; for example, incubation of G2-arrested FT210 cells with the protein phosphatase 1 and 2A inhibitor okadaic acid induces several landmark events of early mitosis, including chromosome condensation, nuclear lamina depolymerization, and centrosome separation (Gowdy et al., 1998) . We examined the effect of okadaic acid treatment of G2-arrested cells on the activities of Plk1 and MAP kinase, as activation of these kinases potentially contributes to the early mitotic phenotypes observed in the absence of Cdc2 activity. FT210 cells were arrested at either G2 or M phase and cell lysates were prepared. The activation of Plk1 was assessed by both Western blotting and assay of Plk1 activity. Plk1 activity is regulated by phosphorylation and dephosphorylation (Lee et al., 1995; Lane and Nigg, 1997) , and the phosphorylated form migrates more slowly on SDS-PAGE. Plk1 from cells arrested at mitosis with nocodazole was phosphorylated, as shown by the slower migrating form, whereas no phosphorylated Plk was detected in G2-arrested cells at the nonpermissive temperature (Figure 1a , top panel). To After double-thymidine block to arrest cells at the G1/S boundary, HeLa cells were released into fresh DMEM medium for 2 h when 100 mM of PD was added. Cells were collected at the times indicated and analysed for phosphorylation of Plk1 by PAGE and immunoblotting Requirement of MAP kinase pathway for cell survival X Liu et al directly examine its kinase activity, Plk1 was immunoprecipitated from cell lysates, and incubated with GST-TCTP. In concordance with the Western blot, Plk1 from nocodazole-treated cells had about sevenfold higher GST-TCTP phosphorylation activity than that from G2-arrested cells ( Figure 1a , middle panel). When G2-arrested cells were treated with 0.5 mM okadaic acid for 2 h, Plk was partially activated, as indicated by both the appearance of a doublet in the Western blot and elevated GST-TCTP phosphorylation activity ( Figure 1a , lane 3). Compared to that from untreated cells, Plk activity increased nearly threefold upon okadaic acid treatment.
To confirm the absence of Cdc2 activity at 391C, Cdc2 was immunoprecipitated from cell lysates, and its kinase activity was measured using histone H1 as a substrate. As expected, mitotic Cdc2 has much higher H1 phosphorylation activity than that from G2-arrested cells, and okadaic acid treatment did not elevate its activity at 391C ( Figure 1a , bottom panel). Thus, the okadaic acid-induced activation of Plk1 at the nonpermissive temperature occurred in the absence of changes in Cdc2 activity.
PD98059 (PD) is a specific inhibitor of Mek activity in vitro and in vivo (Alessi et al., 1995) . To test the effect of PD on okadaic acid-induced Plk1 activation, G2-arrested cells were incubated with PD for 2 h before okadaic acid treatment. Activation of Plk1 was examined by both Western blot and IP-kinase assay; the addition of PD blocked the activation of Plk1 by okadaic acid (Figure 1a , lane 4).
Activation of MAP kinase pathway by okadaic acid
The MAP kinase cascade is inhibited by an okadaic acid-sensitive threonine phosphatase as well as an okadaic acid-insensitive tyrosine phosphatase (Sohaskey and Ferrell, 1999) . Therefore, we investigated whether the MAP kinase cascade is also activated in okadaicacid-treated FT210 cells at the restrictive temperature.
Lysates from cells at different stages of the cell cycle were analysed with antibodies against phosphorylated Mek and phosphorylated Erk ( 
Inhibition of Plk1 activation by PD
The inhibition by PD of okadaic acid-induced Plk1 activation at the restrictive temperature in FT210 cells suggests that MAP kinase may be involved in the G2/M transition of mammalian cells. To further examine the potential role of the MAP kinase cascade during cell phases other than G1, HeLa cells were double-thymidine blocked to induce arrest at the G1/S boundary and then released into fresh DMEM. After 2 h release PD was added, and cells were harvested at various times and subjected to FACS analysis. About 80% of cells had a G2 DNA content 10 h after release, and the addition of PD had no obvious effect on cell phase distribution before 10 h. However, a significant difference was observed at later times after release. At 14 h after release from the G1/S boundary, about 90% of control cells had completed mitosis and returned to G1, whereas a significant number of PD-treated cells continued to be arrested with a 4 N DNA content (data not shown). We also tested the effect of PD on Plk1 activation after HeLa cells were released from the double-thymidine block (Figure 1c) . At various times, cell lysates were resolved by PAGE and immunoblotted with anti-Plk1 antibody. The presence of PD strongly inhibited the phosphorylation of Plk1 (Figure 1c , compare lanes 1 and 2, lanes 3 and 4).
Colocalization of Plk1 with hyperphosphorylated Mek1/2
To further evaluate a role for the MAP kinase pathway in normal mitotic progression, HeLa cells were arrested at prometaphase with monastrol, and released into fresh medium. Cells were harvested at various times and subjected to immunofluorescence staining with antibodies against Plk1 and phospho-Mek1/2 (Figure 2 ). At prometaphase, phospho-Mek1/2 colocalized with Plk1 at centrosomes (Figure 2 , top panel) and spindle poles (Figure 2 , second panel). Strong phospho-Mek1/2 staining was detected at the midzone at anaphase, matching Plk1 localization perfectly at this stage (Figure 2, third and fourth panels). Finally, Plk1 was concentrated at the midbody during telophase/cytokinesis, and elevated phospho-Mek1/2 signals were also detected at the same area (Figure 2 , two bottom panels). These data suggest a possible requirement for the MAP kinase pathway in normal progression through mitosis as well as in activation of Plk1.
Mek1 does not directly phosphorylate Plk1
In view of colocalization of phospho-Mek and Plk1 at mitotic structures, we tested whether Mek1 can directly activate Plk1 by ectopic expression of Mek1 in mammalian cells. Mutations of serine-218 and -222 of Mek1 to either aspartate (DD) or valine (VV) result in constitutively active or kinase dead Mek1, respectively (Huang and Erikson, 1994) . We found that ectopic expression of either Mek1-DD or -VV did not cause significant activation of either Cdc2 or Plk1 (data not shown). To test if Mek1 can directly phosphorylate Plk1 in vitro, the two forms of Mek1 were expressed in baculovirus-infected insect cells. Cell lysates were immunoprecipitated with anti-EE antibody, and IP pellets were incubated with purified GST-Plk1-KM (kinase dead) in the presence of [g- Autophosphorylation of EE-Mek1-DD was easily detected, while no obvious Plk1 phosphorylation was observed (data not shown), indicating that Mek1 does not directly phosphorylate Plk1 in vitro.
Phenotype of Raf1 depletion
To further examine the function of the MAP kinase pathway, we used the recently developed vector-based RNAi technology to specifically deplete Raf1 (Sui et al., 2002) . We targeted human Raf1 at the coding region 122-142 relative to the first nucleotide of the start codon. The vector pBS/U6-Raf1 was transfected into HeLa cells, and the cells were cultured for 48 h. Cell lysates were prepared and standard Western blotting was performed. The level of Raf1 protein was reduced by at least 80% after 48 h transfection, demonstrating the efficiency of the vector-based RNAi approach ( Figure 3a , top panel), whereas the level of Erk2 was unchanged ( Figure 3a , bottom panel).
Since the transfection efficiency varied significantly for different experiments, we cotransfected pBabe-Puro, which contains a puromycin-resistance gene, to select the transfection-positive cells. After 36 h selection with puromycin, most untransfected cells were dead, and the surviving cells were used for phenotype analysis. We first tested whether Raf1 depletion affects cell growth.
Transfection with pBS/U6-Raf1-1st and pBabe-Puro did not influence proliferation, whereas the depletion of Raf1 strongly inhibited cell growth (Figure 3b ). We also assessed the viability of Raf1-depleted cells. Transfection with the control vector showed very little effect on cell survival, whereas only 13% of Raf1-depleted cells still attached to the culture dish after 96 h transfection (Figure 3c ). Finally, we analysed the effect of Raf1 depletion on cell cycle progression using fluorescenceactivated cell sorting (FACS). As shown in Figure 3d , transfection of control vector did not affect the cell cycle profile, whereas Raf1 depletion induced an obvious increase in the percentage of cells with 4 N DNA content. At 60 h post-transfection, approximately 75% of Raf1-depleted cells had a 4 N DNA content compared to 10% in control vector-transfected cells. Moreover, cells with sub-G1 DNA content also increased dramatically at later stages post-transfection, suggesting that Raf1-depleted cells undergo apoptosis (Figure 3d) . At 72 h post-transfection, about 45% of Raf1-depleted cells had been released into the culture medium compared to 3% of control vector-transfected cells. About 90% of Raf1-depleted cells appeared apoptotic at 96 h posttransfection, whereas less than 5% of control cells had this phenotype. To confirm that the apoptosis phenotype we observed in Raf1-depleted cells by FACS analysis was indeed apoptosis, anticaspase 3 Western blotting was performed (Figure 3e ). Caspase 3, the executioner caspase in apoptosis, was activated, as shown by the cleavage of full-length protein.
Cdc2 and Plk1 activities of Raf1-depleted cells
Since Raf1 depletion caused cell cycle arrest with 4 N DNA content, we next analysed the Plk1 activity of Raf1-depleted cells. To prepare Raf1-depleted cells, HeLa cells were cotransfected with pBS/U6-Raf1 and pBabe-Puro at a ratio of 9 : 1, as described in Materials and methods. After selection of transfected cells with puromycin for 36 h, the floating cells were removed, and the remaining attached cells were harvested as Raf1-deficient cells (60 h post-transfection). As a control for Plk1 activity during the cell cycle, HeLa cells were double-thymidine blocked first, then released into fresh medium for different times (Figure 4a ). Plk1 activity was very low at the time of release, and increased during S (4 h release) and G2 (6 h release). The significant increase of Plk1 activity occurred at late G2 phase (8 h release), and the maximum level of Plk1 activity was detected at mitosis (10 h release into nocodazolecontaining medium). The Plk1 activity of Raf1-depleted cells was comparable to that of mitotic cells (Figure 4a , compare lanes 6 and 5), and was about 11-fold higher than that of G1 cells (Figure 4a, bottom panel) . Moreover, nocodazole treatment of Raf1-depleted cells did not further increase Plk1 activity (Figure 4a, lane 7) . We then examined Cdc2 activity in Raf1-depleted cells. Raf1-depleted cells were prepared in the same way as shown in Figure 4a . As shown in Figure 4b , Cdc2 activity was 2.5-fold greater in Raf1-depleted cells than in randomly growing cells, whereas Cdc2 activity in cells arrested in M phase with nocodazole was about fivefold higher. We also analysed Raf1-depleted cells after costaining with anti-a-tubulin antibody and DAPI (Figure 4c ). Four types of cells were categorized: cells with tubulin network and decondensed DNA, cells with tubulin network and fragmented DNA, characteristic mitotic spindle structure with condensed DNA, and mitotic spindle structure with fragmented DNA. Quantification showed that 70% of Raf1-depleted cells had network tubulin staining, while 30% of Raf1-depleted cells (including both condensed DNA and apparently fragmented nuclei) had a characteristic mitotic spindle structure. This is consistent with phosphohistone H3 staining of Raf1-deficient cells described below ( Figure 11 ). As shown in Figure 3d , about 75% of Raf1-depleted cells had a 4 N DNA content. These data suggest about 50% of Raf1-deficient cells arrested at late G2, whereas the remainder blocked in M phase. Thus, Plk1 activation is required, but not sufficient for entry into mitosis. With regard to the cells with fragmented nuclei, 15% (3% of total) showed network tubulin, while 85% (17% of total) displayed mitotic spindle structures. The fact that a higher percentage of mitotic cells were undergoing apoptosis suggests that travel through G2/M may be a key step to determine the fate of a cell, death or survival.
We next assessed the effects of Mek activation or inhibition on the phenotypes of Raf1-deficient cells. To achieve Mek1 activation in Raf1-deficient cells, Hela cells were Raf1-depleted first, and then transfected with a constitutively active form of Mek1 (pCI-neo-EEMek1-DD) on the following day. Cells were harvested after 1 additional day incubation, and Cdc2 activity was analysed (Figure 5a ). Ectopic expression of Mek1-DD partially reversed the Raf1-depletion-induced Cdc2 activation, suggesting that Mek1-DD-expressing cells re-enter G1. Finally, we examined Plk1 and Cdc2 activities after incubation of Raf1-deficient cells with PD or U0126 for 10 h prior to harvest (Figure 5b and c) . The addition of Mek inhibitors decreased both Plk1 and Cdc2 activities of Raf1-deficient cells, probably due to a further complete block of the MAP kinase pathway. We did not observe the significant increase of Erk activity after Raf1 depletion (Figure 5d ), suggesting that the increased Plk1 and Cdc2 activities are not due to a compensatory increase in Mek/Erk activity in the Raf1-deficient cells. 
Phenotype of Mek1 or 2 depletion
A similar approach was used to deplete Mek1 or 2 ( Figure 6 ). The vectors pBS/U6-Mek1, pBS/U6-Mek2 or both pBS/U6-Mek1 and pBS/U6-Mek2 were transfected into HeLa cells, and the cells were incubated for 72 h post-transfection. Cell lysates were prepared and standard Western blotting was performed. Transfection with pBS/U6-Mek1 or Mek2 specifically depleted the relevant enzyme, whereas the level of the other was unchanged (Figure 6a , left and middle panels). Thus, either Mek1 or Mek2 can be independently depleted, and cotransfection of pBS/U6-Mek1 with pBS/U6-Mek2 depleted both Mek1 and 2 (Figure 6a , right panels). We first tested whether Mek1 or 2 depletion affects cell growth. HeLa cells were transfected with pBS/U6-Mek1 or 2 and pBabe-Puro at a ratio of 9 : 1 and selected with puromycin as described above. On day 3 post-transfection, the floating cells were removed, and the remaining cells were cultured up to day 6 posttransfection in the presence of puromycin. The depletion of Mek1 strongly inhibited cell growth, whereas inhibition was less striking in Mek2 À cells (Figure 6b ). We then examined the viability of Mek1-or 2-depleted cells. Transfection with the control vector showed very little effect on cell survival, whereas depletion of either Mek1 or 2 caused cell death in the later times post-transfection (Figure 6c ). Furthermore, Mek1 was more critical than Mek2 for cell survival, consistent with their different effects on cell growth. We examined the effect of Mek1/ 2 depletion on cell cycle progression using FACS. As shown in Figure 6d , the transfection of control vector did not affect the cell cycle profile during the 6 d period, whereas Mek1 or 2 depletion induced obvious changes. Mek1 depletion caused a rapid increase in the percentage of cells with 4 N DNA content at early times of depletion (days 3, 4 post-transfection), and an increase in subgenomic DNA content at later stages (days 5, 6 post-transfection), suggesting that Mek1-depleted cells undergo apoptosis. In contrast, Mek2-depleted cells did not show signs of G2/M arrest (4 N DNA content) up to 6 days of incubation, but they did display subgenomic DNA at day 5 post-transfection. It is possible that Mek2 influences entry into S phase, as suggested by the limited increase of cell number and the absence of a cell 5) . For lanes 6 and 7, Raf1-depleted cells were prepared as described above, and harvested at 60 h post-transfection. Nocodazole (200 ng/ml) was also included in the medium for 10 h before harvesting for lanes 5 and 7. About 1 mg of cell lysate was subjected to anti-Plk1 IP/kinase assay using GST-TCTP as substrate. (b) HeLa cells were harvested after either random growth (interphase), treatment with 200 ng/ml nocodazole for 14 h (mitosis), or Raf1 depletion (Raf1 À ). About 1 mg of cell lysate was used for anti-Cdc2 IP/kinase assay using histone H1 as substrate. (c) Raf1-depleted cells on coverslips were costained with anti-a-tubulin antibody and DAPI. Cells were grouped into four categories (top to bottom): cells with tubulin network and decondensed DNA; cells with tubulin network and fragmented DNA; characteristic mitotic spindle structure with condensed DNA; mitotic spindle structure with fragmented DNA. One representative cell from each category is shown. Scale bar: 10 mm. Quantification indicated that 30% had a mitotic spindle structure, of which 17% had fragmented DNA, and 70% showed a tubulin network, of which 3% had fragmented DNA Requirement of MAP kinase pathway for cell survival X Liu et al population with increased 4 N DNA content. Anticaspase-3 Western blotting at day 4 post-transfection supported the apoptosis phenotype we observed in Mek1-or 2-depleted cells by FACS analysis (Figure 6e ).
Mek1/2 inhibition induced cell death
To independently confirm that RNAi-based depletion of the MAP kinase pathway members induced growth inhibition and apoptosis, we also utilized two wellknown Mek1/2 inhibitors PD and U0126. Exponentially growing HeLa cells were incubated with either DMSO, PD or U0126, and harvested at different times. Treatment of cells with DMSO did not affect cell proliferation, whereas both PD and U0126 treatment significantly inhibited cell growth (Figure 7a ). An obvious decrease of cell viability was observed for PDand U0126-treated cells, although PD showed a more severe lethal effect than U0126 (Figure 7b ). In the FACS profiles, we found that 24 h PD treatment induced a strong G1 arrest. Compared to 53% of control cells with G1 DNA content, cells with G1 content increased to 81% after 24 h PD treatment, whereas S-phase cells decreased from 20% in the control to 7% in PD-treated cells (Figure 7c, inserts) . Cells with subgenomic DNA content increased dramatically after 48 h PD treatment, and only 6% of cells were still viable after 60 h PD treatment. In the same experiment, U0126 did not strongly arrest cells in G1, but obvious cell death was detected after 60 h treatment.
Cdc2 and Plk1 activities of Mek1-or 2-depleted cells
To further distinguish whether Mek1 depletion caused G2-or M-phase arrest, we next analysed Cdc2 and Plk1 activities of Mek1-or 2-depleted cells. HeLa cells were cotransfected with pBS/U6-Mek1 or 2 and pBabe-Puro, selected with puromycin for 2 days, and the attached cells were harvested for Cdc2 and Plk1 IP/kinase assays. To analyse the effect of nocodazole on Mek1-or 2-depleted cells, 100 ng/ml of nocodazole was added to the medium for 10 h prior to harvest. Compared to randomly growing cells, both Cdc2 and Plk1 activities of Mek1-depleted cells decreased slightly (Figure 8a and b), indicating that Mek1-depleted cells arrested in G2, not in M phase. Interestingly, both Cdc2 and Plk1 activities of Mek2-depleted cells were about 50% of those of randomly growing cells, suggesting that Mek2-deficient cells may arrest in G1. Finally, we analysed the effect of nocodazole treatment on Mek1-or 2-depleted cells. As shown in Figure 8c , Cdc2 activities of nocodazole-treated Mek1-or 2-depleted cells remained low, suggesting that Mek1-or 2-depleted cells do not enter mitosis even after nocodazole treatment. In agreement with this, Plk1 activities of these cells were also much lower than that of mitotic cells (Figure 8d ).
Phenotype of Erk1 or 2 depletion
We continued to analyse the potential function of the MAP kinase pathway during mitosis using the same protocol to deplete Erk1 or 2 with the vector pBS/U6-Erk1 or 2. Transfection with pBS/U6-Erk1 significantly depleted Erk1, whereas the level of Erk2 remained constant (Figure 9a, left panel) . The level of Erk2 was dramatically decreased after transfection with pBS/U6-Erk2, whereas the Erk1 level was not affected (Figure 9a , middle panel). Thus, either Erk1 or Erk2 can be specifically depleted, while the other is not affected. Codepletion of Erk1 and 2 was achieved by cotransfection of pBS/U6-Erk1 and pBS/U6-Erk2 (Figure 9a , right panel). The effect of depletion on cell growth and viabilities was assessed. As shown in Figure 9b , obvious cell growth inhibition was observed after depletion of either Erk1 or 2. The viability of Erk1 or 2-depleted cells also decreased dramatically, and no obvious difference was observed for cells depleted of either Erk1 or 2 HeLa cells were harvested after either random growth (interphase), treatment with 100 ng/ml nocodazole for 12 h (mitosis), Mek1 depletion (Mek1 À ), or Mek2 depletion (Mek2 À ). About 1 mg of cell lysate was used for anti-Cdc2 IP/kinase assay using Histone H1 as substrate (a), or anti-Plk1 IP/kinase assay using GST-TCTP as substrate (b) 
À ) cells were treated with 100 ng/ml of nocodazole for 12 h before harvest. Cell lysates were subject to anti-Cdc2 IP/kinase assay (c), or anti-Plk1 IP/kinase assay (d) Requirement of MAP kinase pathway for cell survival X Liu et al (Figure 9c ). FACS analysis revealed that Erk1 depletion caused an obvious increase of percentage of cells with 4 N DNA content at an early stage of depletion (72 h, 84 h post-transfection), and of subgenomic DNA content at a later stage of depletion (96 h post-transfection). In contrast, apoptosis was observed in Erk2-depleted cells as early as 72 h after transfection, and G2/M arrest was not evident when compared to control cells (Figure 9d ).
Cdc2 and Plk1 activities of Erk1/2-depleted cells
We assessed Cdc2 and Plk1 activities of Erk1-or 2-depleted cells to determine whether Erk1 depletion caused G2 or M phase arrest. We did not observe a significant increase of either Cdc2 or Plk1 activity in Erk1-depleted cells, indicating that Erk1-depleted cells arrested at G2 phase, not in M phase (Figure 10a and b, lanes 1-3). As observed for Mek1-or 2-depleted cells, nocodazole treatment did not result in an increase in Cdc2 activity (Figure 10a , lanes 4-6), indicating that Erk1-or 2-depleted cells do not enter mitosis even after nocodazole treatment. As expected, Plk1 activities of Erk1-or 2-depleted cells remained low after nocodazole treatment (Figure 10b , lanes 4-6).
Phosphohistone H3 staining of cells with depleted MAP kinase pathway members
As shown above, both Cdc2 and Plk1 activities of nocodazole-treated cells with depleted Mek1 or 2 (Figure 8 ), Erk1 or 2 ( Figure 10 ) were significantly lower than those of normal mitotic cells. To further confirm this observation, we used antiphosphohistone H3 antibody, a well-known mitosis marker (Ajiro et al., 1996) , to analyse the response of MAP kinase pathwaydepleted cells to nocodazole treatment (Figure 11 ). Only about 3% of asynchronous cells showed positive phospho-H3 staining, while treatment with 100 ng/ml of nocodazole for 10 h caused up to 60% of cells with positive phospho-H3 staining. Consistent with the data shown above (Figure 4) , 23% of Raf1-depleted cells showed positive phospho-H3 staining, while about 70% of cells appear to be in interphase. More interestingly, no significant increase of phospho-H3 positive staining was observed for Raf1-depleted cells after nocodazole treatment. Finally, very few phospho-H3-positive cells were observed after depletion of Mek1 or 2, Erk1 or 2, even after nocodazole treatment. In conclusion, cells depleted with MAP kinase pathway members no longer respond to nocodazole treatment.
Discussion
Mouse FT210 cells, which harbor a temperaturesensitive mutation in the Cdc2 gene, cannot enter mitosis but arrest at G2 at the nonpermissive temperature. Previous reports have shown that treatment of these cells with okadaic acid induces chromosome condensation, nuclear envelope breakdown, and centrosome separation (Guo et al., 1995; Gowdy et al., 1998) . These events were inhibited by tyrosine phosphatase inhibitors as well as protein kinase inhibitors, suggesting that protein kinases other than Cdc2 are required for these mitotic events. In this communication, we have demonstrated that Plk1 was activated during the okadaic acid-induced mitotic entry of FT210 cells in the absence of Cdc2 activity (Figure 1a ), indicating that Cdc2 activity is dispensable for Plk1 activation. In this regard, we recently reported the phenotype of mammalian cells after Plk1 depletion using RNAi Erikson, 2002, 2003) . In Plk1-depleted cells, Cdc2 activity is similar to that of nocodazole-treated cells, probably due to the stabilization of cyclin B (Liu and Erikson, 2002) . Thus, in HeLa cells, Plk1 activity is also dispensable for Cdc2 activation.
We have presented evidence to show that the MAP kinase pathway was activated when FT210 cells were Figure 10 Cdc2 and Plk1 activities of Erk1/2-depleted cells. HeLa cells were subjected to either Erk1 depletion (lanes 2, 5), Erk2 depletion (lanes 3, 6), or left untreated (lanes 1, 4), then incubated with 100 ng/ml nocodazole for 12 h (lanes 4 to 6) before harvest. About 1 mg of cell lysate was used for anti-Cdc2 IP/kinase assay using histone H1 as a substrate (a), or anti-Plk1 IP/kinase assay using GST-TCTP as a substrate (b) Figure 11 Phospho-histone H3 staining of cells with depleted MAP kinase pathway members. (a) HeLa cells were treated as indicated on the left, and subjected to antiphosphohistone H3 staining. DNA was stained with DAPI. Scale bar; 20 mm.
(b) Quantification of results
Requirement of MAP kinase pathway for cell survival X Liu et al treated with okadaic acid at the restrictive temperature, suggesting that, in addition to the Plk1 pathway, the MAP kinase pathway is also required for mitotic entry (Figure 1b) . PD, when added during S phase, was shown to induce G2 arrest in NIH3T3 cells as well as to attenuate Cdc2 kinase activity (Wright et al., 1999; Hayne et al., 2000) . Therefore, the effect of PD on Plk1 activation shown in Figure 1c was most likely a secondary effect of G2 arrest. In agreement with data obtained from PD experiments, depletion of Mek1 or Erk1 by use of RNAi also caused cell cycle arrest in G2 (Figures 8 and 10) , as evidenced by an increase in the percentage of 4 N DNA content in FACS profiles, and a decrease of Cdc2 activity compared to randomly growing cells.
Previous reports implicate the involvement of the MAP kinase pathway during mitosis. In studies with Xenopus oocytes, MAP kinase is required for oocyte maturation and it has been reported to be necessary for normal mitotic progression in Xenopus egg extracts (Haccard et al., 1995; Guadagno and Ferrell, 1998) . Antibody directed at phosphorylated, active MAP kinase reveals that it localized at kinetochores, asters, and the midbody during somatic cell mitosis (Shapiro et al., 1998; Zecevic et al., 1998) . Here, we have provided additional data to show the colocalization of active Mek1/2 with Plk1 at the mitotic apparatus of somatic mammalian cells. Activated Mek1/2 colocalized with Plk1 at spindle poles during prometaphase, and at later stages of mitosis, phospho-Mek1/2 concentrated at the midzone (anaphase), then at the midbody (telophase and cytokinesis), matching the location of Plk1 (Figure 2) .
The results reported here are consistent with previous data that demonstrate a good correlation between activation of the MAP kinase cascade and promotion of cell proliferation. In this study, we showed that depletion of any of the five members of MAP kinase pathway, Raf1, Mek1 or 2, Erk1 or 2, significantly inhibits cell proliferation and viability. Antisense Raf1 or inhibitory Raf1 had been shown to interfere with NIH-3T3 cell proliferation, whereas constitutively activated Raf1 accelerated proliferation (Miltenberger et al., 1993 ). An animal model using knockout technology also provides insights into Raf1 functions. Developmental defects were observed in the placenta as well as in the skin and lungs of Raf1 knockout embryos, and Raf1 mutants display a generalized growth retardation (Wojnowski et al., 1998) . Similar linkage was also reported between cell growth and other members of MAP kinase pathway. Ectopic expression of kinasedefective Mek1 inhibits the activation of Erk1/2 and growth factor-induced proliferation (Cowley et al., 1994) . Dominant-negative approaches with both expression of kinase-deficient Erk1 and transfection of antisense RNA against Erk1 revealed that growth factor activation of Erk1/2 is an absolute requirement for triggering the proliferation response (Pages et al., 1993) . In line with the data obtained with RNAi approach, treatment with Mek inhibitors also inhibited cell proliferation and caused cell death.
FACS analysis of MAP kinase pathway-depleted cells provides more information to explain the effect on cell proliferation and survival. Cell cycle arrest with 4 N DNA content of Raf1, Mek1, Erk1-depleted cells suggests that the growth retardation of these cells is due to arrest at a later phase, not an early phase, of the cell cycle. Biphasic activation of the MAP kinase pathway during the cell cycle of mammalian cells has been previously documented. These reports show that Erk1/2 had enhanced activities in the G1 through S and G2/M phases, and were activated biphasically in the G1 phase and around the M phase (Tamemoto et al., 1992) . More recently, the kinase activities of Raf1, Mek1/2, and Erk1/2 were all shown to have two peaks, corresponding to the G1 phase and late G2/early mitosis, respectively (Harding et al., 2003) . Simultaneous inhibition of Mek1 and 2 caused G1 arrest (Figure 7c ), whereas specific depletion of Mek1 led to a G2 block (Figure 6d ). This suggests that Mek2 may compensate for the loss of Mek1 during early phases of cell cycle, but not for the G2/M transition. The obvious apoptosis at later stages of MAP kinase pathwaydepleted (or -inhibited) cells indicated that all the five MAP kinase pathway members are essential for cell survival. Genetic studies have demonstrated that embryonic lethality in Raf1 knockout animals is due to extensive apoptosis, while cell proliferation and response of MAP kinase to growth factors are not affected (Wojnowski et al., 2000) . Embryonic lethality is also observed in Mek1-deficient mice, apparently due to an essential role for Mek1 in angiogenesis in the labyrinthine region of the placenta (Giroux et al., 1999) . However, Mek2 knockout mice were reported to be viable, fertile and did not present obvious morphological alterations (Belanger et al., 2003) , suggesting that Mek2 is dispensable for growth and development, and the loss of Mek2 may be compensated by Mek1 in the mouse. The obvious contrast between our Mek2-depletion data and the previous knockout results may be due to the different cell types and species examined. We used human tumor cells in this study, and the previous knockout work focused on primary embryonic fibroblasts and T cells of murine origin. Thus, it will be of future interest to extend our approach to deplete MAP kinase pathway members in primary human and murine cells. Finally, we noticed that accumulation of 4 N DNA precedes the appearance of sub-G1 DNA in RNAi-depleted cells. This suggests that travel through the G2 phase is a key step for cells to decide whether to survive or die.
Measurement of Cdc2 and Plk1 activities of cells depleted of MAP kinase pathway members further revealed the functional differences between the five members of the pathway during later phases of the cell cycle. Although Raf1-depleted cells had elevated Cdc2 and Plk1 activities, the majority of the population arrested at late G2. Mek1-or Erk1-depleted cells also arrested at G2, suggesting that all these three gene products are essential for mitotic entry. In contrast, Mek2-or Erk2-depleted cells appear to arrest at the G1 phase, as evidenced by the slow cell growth and low Cdc2 and Plk1 activities. These data indicate that Mek1 and 2, as well as Erk1 and 2, have distinct roles in cell cycle progression, which is in contrast to the traditional view that they have identical functions in cultured cells. It is important to note that the populations of cells described here are somewhat heterogeneous, as the transfections were carried out with unsynchronized cultures. Among the five gene products we depleted, Raf1 depletion caused the most dramatic defects. This suggests that Raf1 may also activate other pathways in addition to Mek/Erk that influence cell proliferation and survival. Raf1-deficient cells also showed greater Plk1 and Cdc2 activities than those of Mek/Erk-deficient cells. However, fluorescent staining of chromatin, tubulin, and phospho-histone H3 indicated that about 50% of Raf1-deficient cells with 4 N DNA content were arrested in G2, while the rest were in M phase. Since we did not observe a significant increase of Erk activity in Raf1-depleted cells, the increased activities of Plk1 and Cdc2 are not due to a compensatory increase in Mek/ Erk activity in Raf1-depleted cells.
Abbreviations Plk1, polo-like kinase 1; TCTP, translationally controlled tumor protein; MBP, mylein basic protein; IP, immunoprecipitation; GST, glutathione S-transferase; RNAi, RNA interference; MAPK, mitogen-activated protein kinase; Mek, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; Erk, extracellular signal-regulated kinase.
